Who mentions $RVMD most on Surfaced?

@adamfeuerstein (Adam Feuerstein ✡️) mentions $RVMD most — 49 mentions in the past 12 months.

When was $RVMD first mentioned on Surfaced?

The earliest tracked mention of $RVMD in the Surfaced archive was on Jul 24, 2025.

How many voices track $RVMD?

4 FinTwit voices have mentioned $RVMD 73 times in the past 12 months.

What kind of voices mention $RVMD most?

$RVMD is mentioned most by Biotech voices on Surfaced.

$RVMD — FinTwit mentions on Surfaced

Recent calls

16 calls

@jacobpliethJun 8, 2026 · 12:06 PM

Some context for that 92% ORR / 90% 6mth landmark PFS in pancreatic cancer for the $TNGX vopimetostat + daraxonrasib combo: vopimetostat monorx 25% ORR, ~90% 6mth PFS $RVMD daraxonrasib monorx 32%, 6mth PFS 56% https://t.co/V7RjXlLrZK

Open on X

@adamfeuersteinJun 8, 2026 · 11:58 AM

Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate $TNGX $RVMD https://t.co/jk2fNmqb84 via @DrewQJoseph

Open on X

@adamfeuersteinJun 4, 2026 · 12:16 PM

By showing a near-doubling of overall survival already in the second-line setting, daraxonrasib is an example of a “transformative therapy” that makes conducting future, randomized clinical trials more challenging logistically and ethically, Pazdur said. “If you’re going to do a first-line trial, you have the potential of losing equipoise,” Pazdur said. “People are going to want the drug. Let’s face it, if you have a fatal disease like pancreatic cancer and you are going to die from that disease, you do not want to go on the [control] arm.” Pazdur proposed alterations to $RVMD's current Ph3 trial in first-line pancreatic cancer that could work to expand the drug's use and get it to patients faster. My column linked below has more details... I also spoke w/ RevMed CEO Mark Goldsmith about the same.

Open on X

@adamfeuersteinMay 31, 2026 · 8:32 PM

Incredible #ASCO26 moment. Dr. Brian Wolpin, presenter of the daraxonrasib study, received a standing ovation DURING his talk after he stated the survival benefit for PDAC patients. It was sustained. Cheering. I have never see anything like it in the middle of a talk. $RVMD https://t.co/I2wQfDqsvh

Open on X

@adamfeuersteinMay 30, 2026 · 1:32 PM

Revolution Medicines $RVMD starts shipping experimental pancreatic cancer drug, daraxonrasib. “We don’t have a set number where we are going to cap it. We want to make sure everybody who needs daraxonrasib for pancreatic cancer will receive it. That’s just very, very important for us to do,” CEO Mark Goldsmith told me last night at our #ASCO26 event. Story in post below.

Open on X

@adamfeuersteinApr 27, 2026 · 1:31 PM

$ERAS pan-Ras data update this afternoon after market close. also, $RVMD sent Erasca a letter claiming ERAS-0015 violates certain RevMed patents. https://t.co/QTmyUhT89n

Open on X

@adamfeuersteinApr 23, 2026 · 12:19 PM

This week's Biotech Scorecard: Erasca $ERAS is the poor man's $RVMD (even tho $7B is far from impoverished) Can it be biotech's next big thing? Pan-Ras data next month, right in front of #ASCO26 abstract drop. I spoke to CEO Jon Lim... https://t.co/GckT7X7jdN

Open on X

@adamfeuersteinApr 22, 2026 · 10:20 AM

From $RVMD Revolution Medicines, more strong data on KRAS drug and a glimpse of a ‘novel class’ beyond it Last night's RM-055 data at #AACR26 https://t.co/pfbsXZcOKg via @angRchen

Open on X

@adamfeuersteinApr 21, 2026 · 10:20 PM

At AACR, more strong results for Revolution Medicine’s KRAS drug, plus assurance from NCI’s director https://t.co/YngPC1Aol2 via @statnews #AACR26 $RVMD

Open on X

@jacobpliethApr 15, 2026 · 12:28 PM

Why $RVMD & $ALLO are a microcosm of biotech's historic struggle for success. Some musings from me on @ApexOnco -> https://t.co/3lWgzQplvc

Open on X

@adamfeuersteinApr 15, 2026 · 10:09 AM

$RVMD raised $2 billion!

Open on X

@adamfeuersteinApr 13, 2026 · 2:08 PM

Today's $RVMD study outcome in pancreatic cancer is a good lesson for all the $IBRX @DrPatrick fans. Stop with all the hand-waving "cancer cure" podcasting social media nonsense. Shut up and run well-designed clinical trials with definitive endpoints. If you have a drug that truly helps patients, the data will speak loudly for you.

Open on X

@adamfeuersteinJan 25, 2026 · 7:56 PM

WSJ: $MRK $RVMD deal off https://t.co/OD4cueoX04

Open on X

@adamfeuersteinJan 8, 2026 · 8:47 PM

Our man @mroliverbarnes $MRK $RVMD https://t.co/vUssAaRo5e US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of nearly $19bn, in what would be the latest big deal in the red-hot biotechnology sector. Merck has been pursuing an acquisition of Revolution Medicines, however a deal has not been finalised, according to people familiar with the matter. A tie-up would be at least several weeks away, they added. Other large pharmaceutical groups were still circling the Redwood City-based biotech and another suitor might yet prevail, the people added. A transaction is not a foregone conclusion.

Open on X

@adamfeuersteinJan 7, 2026 · 7:52 PM

$ABBV in advanced talks to acquire $RVMD, per WSJ

Open on X

@adamfeuersteinOct 16, 2025 · 9:06 PM

$RVMD RMC-6236 (pancreatic cancer) among nine drugs awarded an FDA Commissioner’s National Priority Voucher. https://t.co/Vi2p9e7y5T

Open on X

$RVMD

$RVMD

About this stock

Frequently asked

Related stocks